Clinical Trials associated with Hangzhou Ruipu Chenchuang Technology Co., Ltd.
CTR20244750
/ Not yet recruitingPhase 1
评估RGB-5088胰岛细胞注射液治疗1型糖尿病的单中心、单臂、开放性I期临床研究
[Translation] A single-center, single-arm, open-label phase I clinical study evaluating RGB-5088 pancreatic islet cell injection for the treatment of type 1 diabetes
评价RGB-5088胰岛细胞注射液移植治疗1型糖尿病患者的安全性和疗效
[Translation]
To evaluate the safety and efficacy of RGB-5088 pancreatic islet cell injection and transplantation in patients with type 1 diabetes
A Single-Center, Single-Arm, Open-Label Phase I Clinical Trial Evaluating the Safety and Efficacy of RGB-5088 Islet Cell Injection in the Treatment of Type 1 Diabetes Mellitus
This Phase I clinical trial is a single-center, single-arm, open-label study aimed at evaluating the safety and therapeutic efficacy of RGB-5088 islet cell transplantation in patients with Type 1 Diabetes Mellitus.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.